Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of “Buy” by Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC) has earned a consensus rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $10.00.

Several equities research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Piper Sandler cut their price target on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research report on Monday, December 30th. Finally, Guggenheim reissued a “buy” rating on shares of Century Therapeutics in a research report on Wednesday, January 22nd.

Century Therapeutics Trading Down 0.1 %

IPSC opened at $0.60 on Thursday. The stock has a market capitalization of $51.07 million, a P/E ratio of -0.32 and a beta of 1.75. Century Therapeutics has a 12 month low of $0.57 and a 12 month high of $5.24. The firm’s fifty day simple moving average is $0.81 and its 200 day simple moving average is $1.22.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC increased its stake in shares of Century Therapeutics by 56.0% during the 4th quarter. Squarepoint Ops LLC now owns 164,871 shares of the company’s stock worth $167,000 after purchasing an additional 59,174 shares during the last quarter. Two Sigma Investments LP acquired a new position in shares of Century Therapeutics during the 4th quarter worth about $67,000. Two Sigma Advisers LP acquired a new position in shares of Century Therapeutics during the 4th quarter worth about $52,000. Nuveen Asset Management LLC increased its stake in shares of Century Therapeutics by 48.9% during the 4th quarter. Nuveen Asset Management LLC now owns 157,311 shares of the company’s stock worth $159,000 after purchasing an additional 51,661 shares during the last quarter. Finally, Millennium Management LLC increased its stake in shares of Century Therapeutics by 1,041.8% during the 4th quarter. Millennium Management LLC now owns 1,607,174 shares of the company’s stock worth $1,623,000 after purchasing an additional 1,466,415 shares during the last quarter. 50.20% of the stock is currently owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.